{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:05:44Z","timestamp":1759017944661,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.annder.2012.09.015","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T21:34:39Z","timestamp":1351632879000},"page":"828-831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Toxidermie \u00e0 l\u2019imatinib suivie d\u2019une toxidermie au nilotinib"],"prefix":"10.1016","volume":"139","author":[{"given":"M.","family":"Lamchahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Qachouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Benchikhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Benchekroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2012.09.015_bib0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1684\/hma.2009.0351","article-title":"Aspects pratiques des traitements par inhibiteurs de tyrosine kinase dans la leuc\u00e9mie my\u00e9lo\u00efde chronique","volume":"15","author":"Rea","year":"2009","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.annder.2012.09.015_bib0010","first-page":"33","article-title":"Traitement de la leuc\u00e9mie my\u00e9lo\u00efde chronique (LMC) en 2011","volume":"433","author":"Tulliez","year":"2011","journal-title":"Rev Fr Lab"},{"key":"10.1016\/j.annder.2012.09.015_bib0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0151-9638(04)93669-1","article-title":"Toxidermie lich\u00e9no\u00efde \u00e0 l\u2019imatinib (Glivec\u00ae)","volume":"131","author":"Roux","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2012.09.015_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ctrv.2011.07.004","article-title":"Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML","volume":"38","author":"Rosti","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"Spec No. 1","key":"10.1016\/j.annder.2012.09.015_bib0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0151-9638(08)70093-0","article-title":"Effets secondaires cutan\u00e9s des nouvelles mol\u00e9cules anticanc\u00e9reuses\u00a0: focus sur les mol\u00e9cules ciblant les r\u00e9cepteurs tyrosine kinase et le r\u00e9cepteur \u00e0 l\u2019EGF","author":"Deslandresa","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2012.09.015_bib0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.critrevonc.2011.08.002","article-title":"Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions","volume":"82","author":"Valent","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annder.2012.09.015_bib0035","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.annder.2012.09.015_bib0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.annder.2012.09.015_bib0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0151-9638(04)93656-3","article-title":"Effets secondaires cutan\u00e9s de l\u2019imatinib (Glivec\u00ae)","volume":"131","author":"Schmutz","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2012.09.015_bib0050","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clinthera.2010.05.003","article-title":"Treatment options for patients with chronic myeloid leukaemia who are resistant to or unable to tolerate imatinib","volume":"32","author":"Stein","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.annder.2012.09.015_bib0055","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1365-2702.2009.03167.x","article-title":"Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"19","author":"Tinsley","year":"2010","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.annder.2012.09.015_bib0060","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963812005807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963812005807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:59:49Z","timestamp":1758970789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963812005807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0151963812005807"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2012.09.015","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxidermie \u00e0 l\u2019imatinib suivie d\u2019une toxidermie au nilotinib","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2012.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}